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Charles Ilsely baDepartment of Cardiology, Prince Sultan Cardiac Center, Riyadh
bDepartment of Cardiology, Harefield Hospital, London
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b United KingdomObjective: To evaluate the prognosis of primary percutaneous coronary intervention (PPCI) and medical therapy
(MT) in elderly patients presenting with ST-elevation myocardial infarction (STEMI).
Methods: A total of 238 STEMI patients aged above 80 and treated with PPCI (n = 186) andMT (n = 52) at Harefield
Hospital, London were included in this study. Patients who did not have true STEMI based on non-diagnostic elec-
trocardiogram (ECG) for STEMI and negative troponin, who presented with left bundle branch block (LBBB) and
had normal coronaries were excluded from this study. Primary PCI was defined as any use of a guidewire for more
than diagnostic purposes in patients with STEMI, whereas conventional MT was defined as treatment of patients
with anti-platelets and anti-thrombotic medications without thrombolysis.
Results: The survival rate of PPCI patients was 86% (n = 160) at month 1 followed by 83.9% (n = 156) at month 6,
and 81.2% (n = 151) at month 12. The survival rate of MT patients was 44.2% (n = 23) at month 1 followed by 36.5%
(n = 19) at month 6, and 34.6% (n = 18) at month 12. Compared to MT, significantly fewer comorbidities were found in
the PPCI group. Ventricular fibrillation (VF) (4.8%) and consequent admission to intensive care unit (7%) were the
major complications of the PPCI group.
Conclusion: PPCI has a higher survival rate and, compared to MT, fewer comorbidities were observed in the PPCI
group of elderly patients presenting with STEMI.
 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Cardiovascular disease (CVD) is the leadingcause of death worldwide, and coronary
artery disease (CAD) is the most prevalentmanifestation associated with high mortality and
morbidity [1]. Heart failure is the end-stage of sev-
eral cardiovascular diseases such as acute myocar-
dial infarction (AMI), and it remains a major
challenge for regenerative medicine because ofheCCBY-
Abbreviations
PPCI primary percutaneous coronary intervention
PCI percutaneous coronary intervention
MT medical therapy
STEMI ST-elevation myocardial infarction
ECG electrocardiogram
LBBB left bundle branch block
VF ventricular fibrillation
ICU intensive care unit
CVDs cardiovascular diseases
CAD coronary artery disease
AMI acute myocardial infarction
HF Heart Failure
NSTEMI non-ST-elevation myocardial infarction
UA unstable angina
IHD ischemic heart disease
DM diabetes mellitus
COPD chronic obstructive pulmonary disease
HLoS hospital length of stay
BMI body mass index
GUSTO-1 Global Utilization of Streptokinase and Tissue
Plasminogen Activator to treat Occluded Arteries
t-PA tissue plasminogen activator
PAMI-1 Primary Angioplasty in Myocardial Infarction
FU
LL LEN
G
TH
 A
RTIC
LE
86 ALKHUSHAIL ET AL
PERCUTANEOUS CORONARY INTERVENTION IN ELDERLY
J Saudi Heart Assoc
2015;27:85–90its high prevalence and incidence in elderly
patients [2]. However, the long-term incidence of
heart failure (HF) in patients with ST-elevation
myocardial infarction (STEMI), non-ST-elevation
myocardial infarction (NSTEMI), or unstable
angina (UA) is uncertain [3].
Studies report cardiovascular disease as the
leading cause of death in the elderly and describe
its direct correlation with aging [4]. The elderly
may experience higher mortality from STEMI
due to severe comorbidities, advanced CAD, as
well as mechanical and electrical complications
of AMI [5,6]. Further, several disorders often
coexist in the elderly such as ischemic heart
disease (IHD), hypertension, diabetes mellitus
(DM), chronic obstructive pulmonary disease
(COPD), chronic renal failure, digestive system
disorders as well as joint and bone disorders,
which occur more often in this group of patients
[6–10]. Cardiologists are therefore increasingly
confronted with the management challenges of
elderly patients presenting with STEMI. Optional
management of acute coronary syndromes in this
population has been an area of uncertainty as
there is a paucity of evidence-based data due to
their exclusion and under-representation in clini-
cal trials [11].
Primary percutaneous coronary intervention
(PPCI) and pharmacologic therapy are widely
used and constitute a vital treatment strategy for
AMI [12–14]. PPCI therapy must be initiated prior
to angiography (pretreatment), and continued
during the procedure (periprocedural), recovery
phase (in-hospital), and follow-up [15]. The pur-
pose of this study is to evaluate the prognosis of
PPCI and medical therapy (MT) in elderly patients
presenting with STEMI.Table 1. The demographic, BMI and hospital length of stay of
the study population.
Variables Angioplasty Medical
Gender
Male 80 (43%) 27 (52%)
Female 106 (57%) 25 (48%)
Total 186 52
Age
80–85 128 (68.8%) 32
P86–90 42 (22.58%) 14
P91–95 14 (7.52%) 6
P96 2 (1.07%) 0
BMI
Male 24.4 24.3
Female 24.9 25.1
Hospital length of stay
HLOS 3 (2–5 days) 4 (2–7 days)*
* P = 0.039, Mann–Whitney test.Methods
We conducted a retrospective study on 301
STEMI patients (aged P80) treated with PPCI
and MT at Harefield Hospital, London during
the period between January 2005 and February
2010. Sixty-three patients were excluded from
the study as they did not have true STEMI based
on non-diagnostic ECG for STEMI and negative
troponin, or had presented with left bundle
branch block (LBBB) and had normal coronaries.
ST-elevation myocardial infarction was defined
as the presence of ST-elevation or new left bundle
branch block on electrocardiography in addition
to suspicion of ongoing ischemia. Primary PCI
was defined as any use of a guidewire for more
than diagnostic purposes in patients with STEMI.
Conventional MT was defined as treatment with
anti-platelets and anti-thrombotic medications
without thrombolysis. The demographic variables,
body mass index (BMI), comorbidities and hospi-
tal length of stay (HLoS) were also collected for
analysis. The protocol of the study was approved
by the research ethics committee of the hospital.
Data analysis was carried out using Microsoft
Excel 2002 (Microsoft Corporation, Seattle, WA,
USA), and the Statistical Package for Social
Sciences version 16 (SPSS Inc., Chicago, IL,
USA). Data were presented as percentage and
mean ± standard error of mean. Chi-square test
was used to compare the differences between
comorbidities of PPCI and MT, while Mann–Whit-
ney U test was used to compare the HLoS. P-value
of <0.05 was considered statistically significant.
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Demographics, BMI, and hospital length of stay
of the study population are shown in Table 1. A
total of 186 patients were treated with PPCI and
52 patients were treated with conventional MT.
There were 107 (45%) males and 131 females
(54%). The mean age of the PPCI group was
83.92 years and 84.76 years for the MT group
(P > 0.05). The MT group HLoS (four days) was
higher than the PPCI group (three days),Figure 1. Survival rate (%, n) of primary perc
Figure 2. Survival rate (%, n) o
Figure 3. Survival curve: primary percuta(P = 0.039). The survival of the PPCI group is
demonstrated in Fig. 1. The survival rate of PPCI
patients showed 86% (n = 160) at month 1 followed
by 83.9% (n = 156) at month 6, and 81.2% (n = 151)
at month 12. The survival rate of the MT group is
demonstrated in Fig. 2. The survival rate of MT
patients showed 44.2% (n = 23) at month 1 fol-
lowed by 36.5% (n = 19) at month 6, and 34.6%
(n = 18) at month 12. The Kaplan–Meier survival
curves of PPCI are shown in Fig. 3. The comorbidi-
ties of the PPCI and medical groups duringutaneous coronary intervention (n = 186).
f medical therapy (n = 52).
neous coronary intervention patients.
Figure 4. Comorbidity in primary percutaneous coronary intervention (n = 186) and medical therapy group (n = 52).
Figure 5. Complications of primary percutaneous coronary intervention patients (n = 186) during admission.
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2015;27:85–90admission are shown in Fig. 4. Compared to
stroke, Renal Failure (RF) and cancer, hyperten-
sion and DMwere the major comorbidities in both
groups. Compared to MT, significantly fewer
comorbidities were found in the PPCI group.
Complications related to PPCI during admission
are shown in Fig. 5. Ventricular fibrillation (VF)
(4.8%) and consequent admission to intensive care
unit (7%) were the major complications of PPCI.Discussion
The Global Utilization of Streptokinase and Tis-
sue Plasminogen Activator for Occluded Coronary
Arteries (GUSTO-1) trial demonstrated that the
30-day mortality rate for STEMI increased tenfold
among the elderly, from 3.0% in the age group of
<65 years to 30.3% among those >85 years of age
[16]. This high mortality rate in the very elderly
was also confirmed by several other studies [17–
21]. On the other hand, several large multi-center
trials have demonstrated that reperfusion therapy
of STEMI, whether primary percutaneous coro-
nary intervention (PCI) or fibrinolysis, improved
mortality for elderly patients [5]. In the presentstudy, we also observed that treatment with PPCI
was feasible and beneficial for patients with
STEMI.
Limited research has been conducted on the
prognosis of PPCI management of STEMI in the
elderly. There are few trials comparing PPCI with
fibrinolytic therapy, which enroll an adequate
number of older patients. Existing subset analyses
from trials, which randomized patients to primary
PCI or fibrinolytic therapy, suggest that PCI is a
preferred strategy in older patients. The PPCI in
the Primary Angioplasty in Acute Myocardial
Infarction (PAMI-1) study randomized patients
to immediate PCI or fibrinolytic therapy, and
observed that the greatest benefit was in patients
over 65 years. There was no significant reduction
in the combined endpoint of death/MI in patients
under 65 years (0.8% mortality in both groups),
but there was a marked reduction in the same
endpoint in patients >65 (death/MI was 8.6% with
angioplasty versus 20% with tPA) [22]. In the
GUSTO-IIB trial, the largest randomized trial
comparing angioplasty with thrombolytic therapy,
1138 patients were randomized to receive either
accelerated tPA or primary angioplasty. Although
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comes (death/MI (myocardial infraction) 1 stroke
occurred in 9.6% versus 13.7% with tPA), there
was no significant difference in death/MI at six
months (13.3% versus 15%, respectively) [23].
The recent TRatamiento del Infarto Agudo de
miocardio eN Ancianos (TRIANA) trial showed a
trend towards improved outcomes for patients
treated with PCI versus fibrinolysis with a com-
bined end point of death, recurrent MI and dis-
abling stroke at 30 days. PCI patients had
marked improvement of recurrent ischemia. In
the previous SENIOR-PAMI trial, similar results
were obtained, but a subgroup analysis of patients
>80 years of age showed no benefit of PCI over fib-
rinolysis [24]. The present study shows that the
survival rate of PPCI patients was 86% (n = 160)
at month 1, followed by 83.9% (n = 156) at month
6, and 81.2% (n = 151) at month 12. It also suggests
that patients treated with PPCI for STEMI have
good prognosis if they survive the initial months.
A recent study reported that PCI is the preferred
treatment for patients with STEMI owing to
improved vessel patency, decreased infarct size,
lower rates of reinfarction, and improved survival
compared to pharmacological reperfusion [25].
There is little in the literature to direct and guide
STEMI therapy in elderly patients, especially
those whose age is greater than or equal to
80 years [5]. Elderly patients usually have complex
CAD with higher mortality and morbidity, and
higher rates of complication following PPCI, such
as stroke and renal failure [5,26–28]. Advanced
age is an independent predictor of mortality after
PPCI, and elderly patients show a larger preva-
lence of female gender, hypertension, and dia-
betes [17], which was confirmed in our study.
We observed that hypertension and DM were
the major co-morbidities of both the PPCI and
MT groups. Overall, the patients treated with
PPCI had fewer comorbidities compared to the
patients treated with MT, which means that our
hospital had selected the right patients for PPCI
to ensure a better outcome. We also found a ben-
efit in HLoS, which was shorter in the PPCI group.
The MT group HLoS (four days) was higher than
the PPCI group (three days).
Major limitations of this study were the relative-
ly small number of patients, the limited number of
risk factors examined, the study’s retrospective
nature, and that samples were from a single hos-
pital. However, despite its retrospective nature,
the present study is important in light of the pau-
city of evidence-based clinical outcome data due
to research exclusion and under-representationin the elderly STEMI patient group. In future,
absolute and relative risks for efficacy and safety
in age subgroups should be reported and trials
should make an effort to enroll the elderly in pro-
portion to their prevalence among the treated
population. Outcomes of particular relevance to
the older adult, such as quality of life, physical
function, and independence should also be
evaluated and geriatric conditions unique to this
age group, such as frailty and cognitive impair-
ment, should be considered for their influence
on care and outcomes. With these efforts, treat-
ment risks can be minimized and benefits can be
placed within the health context of elderly
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